Qing-Xin Jie-Yu Granules on cardiopulmonary function for patients with heart failure with preserved ejection fraction: a randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000002900

Enrollment

Unknown

Registered

2020-01-05

Start date

2020-01-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with preserved ejection fraction

Interventions

Control group:Qing-Xin Jie-Yu Placebo Granules

Experimental group:Qing-Xin-Jie-Yu Granules

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Both genders aged 40-70 years; 2. Patients with chronic heart failure, NYHA II-III,can complete cardiopulmonary exercise test, whose medications had not been adjusted whthin 2 weeks; 3. LVEF >= 50%; 4. NT-proBNP >= 400pg/mL; 5. Patients signed the written informed consent.

Exclusion criteria

Exclusion criteria: 1. LVEF = 160mmhg, or diastolic pressure >= 100mmhg); 7. Recent recurrence of malignant arrhythmia (paroxysmal ventricular tachycardia); 8. Pregnant, planned pregnant or lactating women 9. Those who participated in other clinical trials in the past 1 month; 10. Allergic constitution or allergy to known ingredients of the test drug.

Design outcomes

Primary

Measure	Time frame
Maximum oxygen uptake;	—

Secondary

Measure	Time frame
6-minute walk test;Minnesota Heart Failure Quality of life scale;Hs-CRP;Cardiac diastolic function;NT-pro BNP;	—

Countries

China

Contacts

Public ContactShengyao Li

Xiyuan Hospital, China Academy of Chinese Medical Sciences

lsycardio@163.com+86 010-62835392

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026